Purpose Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival. Recent reports have suggested that using the triple-drug regimen FOLFIRINOX can substantially extend survival in patients with metastatic disease. We were interested in determining the clinical beneWt of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma.
Introduction
Since 1997, single-agent gemcitabine has been the standard of care for advanced adenocarcinoma of the pancreas and the barometer by which all new therapies are measured [1] . The median overall survival (mOS) of single gemcitabine is approximately 6 months with a response rate of 10% in chemotherapy naïve patients with metastatic disease [1] . At least eight diVerent agents have been evaluated in phase III studies in combination with gemcitabine, including irinotecan, oxaliplatin, cisplatin, docetaxel, erlotinib, bevacizumab and cetuximab [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . None have shown any appreciable survival beneWt, except for gemcitabine and erlotinib, which showed a small but signiWcant beneWt over gemcitabine alone in patients with metastatic disease [8] .
More recently, there has been increased interest, in the use of triple-drug regimens in patients with advanced pancreatic cancer. The combination of biweekly administered Xuorouracil, irinotecan and oxaliplatin in a regimen termed FOLFIRINOX was studied in a phase III trial and was compared with gemcitabine as Wrst-line treatment of metastatic pancreatic adenocarcinoma (n = 342). The FOLFIRINOX arm achieved a response rate of 31.6% and a mOS of 11.1 months [13] .
Another three-drug regimen of interest is a combination that relies on synergy between gemcitabine, capecitabine and docetaxel (GTX), [14] . Optimized by Fine and colleagues, a prospective phase II study demonstrated response rates of 21.9% and a mOS of 14.5 months (n = 43) in advanced metastatic pancreatic adenocarcinoma [15] . Given the accessibility of GTX, many oncologists are now using this regimen on a routine basis. However, the overall beneWt of GTX regimen is not fully understood, especially with the potential for greater toxicity.
Our institutions and others have noted improvements in disease control and survival with GTX in patients with advanced pancreatic adenocarcinoma. To evaluate the clinical beneWt of this regimen, we compiled a large cohort of patients with locally advanced and metastatic disease treated at three diVerent institutions with the GTX regimen and report the observations from this analysis.
Patients and methods

Patient eligibility
Patients with cytologically or histologically conWrmed adenocarcinoma of the pancreas who received GTX regimen at Johns Hopkins Hospital, US Oncology-Dallas and Memorial Sloan Kettering Comprehensive Cancer Center, were included in this study. The retrospective review study was approved by the IRB at each institution. Data were collected by chart review of the patient's medical records using a uniform database format. All data were de-identiWed prior to analysis.
Treatment regimen
The treatment included gemcitabine, docetaxel and capecitabine (GTX) as proposed by Fine and colleagues: capecitabine 750 mg/m 2 /day orally divided into two doses, days 1-14; intravenous (IV) gemcitabine 750 mg/m 2 over 75 min on days 4 and 11 and docetaxel 30 mg/m 2 IV on days 4 and 11. The cycles were repeated every 21 days. Chemotherapy was continued until disease progression, unacceptable toxicity or patient intolerance.
Evaluation of tumor response
CT scans were reviewed in response to treatment after 2-3 cycles of therapy with GTX using the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) was deWned as disappearance of all target lesions. Partial response (PR) was deWned by at least 30% decrease in the tumor load, estimated by the sum of the diameters of target lesions. Progressive disease (PD) was deWned as an increase of at least 20% in the sum of the diameters of target lesions. Stable disease (SD) was deWned as disease that showed neither suYcient shrinkage nor increase to qualify as either PR or PD.
Evaluation of toxicities
Any episodes of chemotherapy-associated hematologic toxicities such as anemia, thrombocytopenia or leukopenia were graded according to the National Cancer Institute Common Toxicity Criteria 4.0 (NCI CTC v4.0). Nonhematologic toxicities such as elevated AST and bilirubin were also assessed. Non-hematological toxicities that resulted in dose modiWcations were also collected. Toxicities were assessed for all cycles of GTX delivered. The number of hospitalizations during GTX treatment, regardless of cause, was recorded.
Statistical analysis
The overall study objective was to evaluate the eYcacy and survival outcomes of a large unselected patient population treated with GTX regimen. Statistical analysis was coordinated by biostatisticians at Johns Hopkins Hospital. Characteristics of patients were descriptively compared between institutions using Wilcoxon rank sum tests or Fisher's exact tests. The frequencies of grade 3/4 toxicities and partial responses, as measured using RECIST criteria, were compared between disease stages, grades and other characteristics with odds ratios that adjusted for patient age, sex, race and institution.
Overall survival was calculated from the time of GTX initiation until death. Patients who were alive at the time of analysis were censored at the date of last observation. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard models were used to assess whether any clinical predictors were independently associated with survival, response or severe grades 3-4 toxicity. All P values are based on two-tailed tests, and P = 0.05 was considered statistically signiWcant. The following variables were assessed: age, performance, number of previous lines of therapy and number of comorbidities.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 (Table S1 ).
The median age of the patients reviewed was 62 years. The majority of patients was metastatic (77%) and had an ECOG performance status (ECOG PS) of 1 (66%). GTX was the Wrst regimen attempted for 51% of cases reviewed, and the average number of cycles completed was 4. Twenty-one percent of patients had prior surgery with curative intent prior to initiating GTX therapy. None of the patients received GTX in the adjuvant setting.
Toxicities
Hematological and non-hematological toxicities were assessed in all treated patients (n = 154) and are shown in Table 2 . No GTX-related deaths were noted. Hospitalization data were available on 50% of patients, of which 33% required at least one inpatient hospitalization while receiving GTX. Nine percent of patients experienced grade 3/4 non-hematological toxicity, and 41% experienced hematological toxicity. Grade 3/4 anemia, neutropenia and thrombocytopenia occurred in 12%, 34% and 13% of patients, respectively ( Table 2) . 
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Grade 3/4 toxicity from GTX was found to be independent of treatment location (Table S3) , stage, grade, ECOG PS, prior surgery, ascites or hospitalization (Table S3 ). Any prior chemotherapy minimally correlated with grade 3/4 toxicity (adjusted odds ratio (OR) 2.01, 95% CI 0.97-4.16, P = 0.057).
Dose reductions and chemotherapy modiWcations were evaluated in half of the patients (77/154). Hematological complications (myelosuppression) resulted in dose reduction in 34% of the patients (26/77). Non-hematological toxicities that resulted in dose modiWcations occurred in 30% of the patients (23/77). The reasons that resulted in GTX dose modiWcations included one or more of the following: fatigue (n = 4) anasarca (n = 2), decreased performance status (n = 2), diarrhea/mucositis (n = 12), intractable nausea/vomiting (n = 3), hand and foot syndrome (n = 2) or multiple procedures required (n = 1).
Response rates
One hundred and forty-six (95%) of the 154 cases were evaluable for response using RECIST criteria [16] . Assessments were performed after every 2-3 cycles of GTX chemotherapy. Partial responses were seen in 11% (n = 16) of patients. Stable disease was seen in 62% of cases (n = 91) and progressive disease in 27% (n = 39). No complete responses were observed. Response rates by extent of disease and line of therapy are summarized in Table 3 .
Elevated ALT, any neutropenia and hospitalization correlated strongly with achieving a partial response (adjusted OR 3.57, 95% CI 0.92-13.8, P = 0.045, ALT elevation; adjusted OR 5.10, 95% CI 0.9-28.91, P = 0.041, any neutropenia; adjusted OR 5.37, 95% CI 1.09-26.51, P = 0.032, hospitalization). A borderline signiWcant correlation with improved response was noted in metastatic patients who received GTX as their Wrst-line therapy (adjusted OR 2.56, 95% CI 0.62-10.59, P = 0.055). Prior chemotherapy negatively correlated with response (adjusted OR 0.16, 95% CI 0.03-0.83, P = 0.012). These Wndings are summarized in Table 4 .
Tumor marker analysis
Longitudinal CA19-9 values for the Wrst two cycles of therapy were available for 86 cases. Patients that did not express CA19-9 were excluded from the analysis. Seventyseven percent (n = 66) of patients demonstrated a measurable decline in CA19-9 after two cycles of therapy with GTX. When GTX was used as Wrst-line therapy (n = 48), a decline CA19-9 was observed in 91% of cases (Fig. 1) . In the second line or greater (n = 38), the CA19-9 response was seen in 63% of cases.
There was no correlation between CA19-9 response, objective radiographic response (Table 4) or survival when measured as a continuous variable ( Figure S1 ). Even when CA19-9 responses were separated into groups using cutoVs deWned by percent decline in CA19-9 levels or by line of therapy, there was no correlation with overall survival (Tables 5, S4 ).
Survival analysis
Chemotherapy naïve patients achieved a mOS of 11.6 months (n = 75) and a 1-year survival of 46% when treated with GTX. Patients who received Wrst-line GTX with metastatic and locally advanced disease achieved a median survival of 11.3 and 25.0 months, respectively (Fig. 2) . In the Wrst-line setting, only ECOG PS correlated with improved survival (adjusted HR 2.57, 95% CI 1.03-6.41, P = 0.043) as shown in Table 5 . When GTX was used as second line or greater (n = 79), the mOS was 5.7 months and 1-year survival was 32% (Table S4 ). In patients with locally advanced disease, the mOS was 16.2 and 5.7 months in metastatic patients. Prior surgery with curative intent (adjusted HR 529.1, 95% CI 3.52-79,433.25, P = 0.014) strongly correlated with improved survival. In the second line setting, experiencing any grade 3/4 toxicity was a negative factor for survival (adjusted HR 0.47, 95% CI 0.25-0.9, P = 0.022).
In the Wrst and second lines of therapy with GTX, there was a marked improvement in survival in patients who demonstrated a RECIST-based partial response (Table 5,  Table S4 ).
Discussion
Advanced pancreatic adenocarcinoma is a genetically complex disease that is uniformly lethal with annual incidence approaching its yearly mortality [17] . Much like other solid tumors, disease progression is most dependent on time as measured by the sequential accumulation of somatic mutations [18, 19] . Despite improvements in the treatment of other solid tumors, the use of combination chemotherapy or the introduction of novel targeted molecules has minimal objective beneWt.
The failure of several phase III trials examining doublet chemotherapy in metastatic pancreatic adenocarcinoma prompted us to examine our use of the triplet, GTX. Originally reported by Fine and colleagues, this regimen combines relatively low doses of gemcitabine and docetaxel in synergy to augment the performance of capecitabine. GTX was optimized in pancreatic cancer cell lines, where capecitabine was sequenced 72-96 h before docetaxel and gemcitabine to achieve maximal tumor kill [14] . Initial human studies demonstrated prolonged survivals in good performance status patients [15] .
Our data are consistent with the previous reports using GTX and other triple-drug regimens and beg the question whether more chemotherapy is better? A series of studies and thrombocytopenia [20, 21] . Whether adding more agents is the best approach remains to be seen, but the primary concern for future adoption of any multiagent regimens appears to be the frequency of signiWcant toxicity. Interestingly, in our cohort, developing toxicities from GTX (any neutropenia, elevated ALT and hospitalizations) were markers for objective radiographic responses. This has been noted with both targeted and conventional chemotherapy regimens where systemic toxicity correlated with clinical response (e.g., skin rash to EGFR inhibitors) and suggests that germ line factors may dictate the sensitivity to this and other such regimens [22] .
Perhaps, the most surprising Wnding is the 25-month survival seen in the Wrst-line setting in patients with unresectable locally advanced disease, which exceeds the median survival in patients undergoing surgical resection [23, 24] . It is also more than twice the survival demonstrated in those patients with metastatic disease receiving Wrst-line GTX. Given these Wndings, it is interesting to speculate that locally advanced and metastatic pancreatic cancer may represent two separate disease entities that may in part be diVerentiated by DPC4 expression [25] . An alternative explanation is that the locally advanced cases may represent a less genetically complex disease state, that is, therefore more susceptible to multiagent chemotherapy [19] .
We were also surprised to Wnd the CA19-9 response did not correlate with survival or response in this cohort of patients, even when examined as a continuous or discrete variable. While more than 75% of the cases reviewed demonstrate CA19-9 decline after two cycles, this did not correspond with a decline in tumor burden. Nonetheless, a Xuctuation in the CA19-9 level does suggest that chemotherapy was reaching the tumor and altering CA19-9 production by tumor or adjacent cells.
In summary, GTX appears to be an active three-drug regimen in advanced adenocarcinoma of the pancreas, in particular, in those patients with therapy-associated toxicity. These Wndings further support future clinical investigation of multiagent regimens, such as GTX, in the treatment of pancreatic cancer.
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